A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression.
Phase of Trial: Phase III
Latest Information Update: 17 Apr 2016
At a glance
- Drugs Quetiapine (Primary)
- Indications Bipolar I disorders; Bipolar II disorders
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Sep 2012 Planned number of patients changed from 294 to 296 as reported by ClinicalTrials.gov.
- 17 Sep 2012 Status changed from recruiting to active, no longer recruiting.